RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Peter R. Hoffmann to Antineoplastic Agents

Back to Details
This is a "connection" page, showing publications Peter R. Hoffmann has written about Antineoplastic Agents.
Peter R. Hoffmann
Connection Strength
0.380
Antineoplastic Agents
  1. Marciel MP, Rose AH, Martinez V, Horio DT, Hashimoto AS, Hoffmann FW, Bertino P, Hoffmann PR. Calpain-2 inhibitor treatment preferentially reduces tumor progression for human colon cancer cells expressing highest levels of this enzyme. Cancer Med. 2018 01; 7(1):175-183.
    View in: PubMed
    Score: 0.309
  2. Weiland F, Arentz G, Klingler-Hoffmann M, McCarthy P, Lokman NA, Kaur G, Oehler MK, Hoffmann P. Novel IEF Peptide Fractionation Method Reveals a Detailed Profile of N-Terminal Acetylation in Chemotherapy-Responsive and -Resistant Ovarian Cancer Cells. J Proteome Res. 2016 11 04; 15(11):4073-4081.
    View in: PubMed
    Score: 0.071
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support